Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 15,254 | 25,747 | 22,735 | 39,084 | 55,203 |
| Marketable Securities | 13,788 | 15,734 | 19,420 | 21,292 | 29,532 |
| Receivables | 56,226 | 47,820 | 48,797 | 39,540 | 38,965 |
| Inventories | 27,995 | 27,102 | 28,369 | 30,546 | 26,403 |
| Income taxes - deferred | 3,967 | 7,533 | 3,683 | 5,589 | 4,751 |
| Other current assets | 0 | 0 | 103 | 74 | 83 |
| TOTAL | $127,834 | $134,046 | $133,003 | $145,687 | $164,893 |
| Non-Current Assets | |||||
| PPE Net | 162,936 | 163,212 | 177,072 | 176,064 | 178,517 |
| Investments And Advances | 956 | 956 | 956 | 956 | 956 |
| Intangibles | 21,809 | 20,640 | 49,984 | 47,996 | 25,276 |
| Other Non-Current Assets | 6,556 | 6,252 | 8,095 | 6,554 | 5,374 |
| TOTAL | $192,257 | $191,060 | $236,107 | $231,570 | $210,123 |
| Total Assets | $320,091 | $325,106 | $369,110 | $377,257 | $375,016 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,541 | 1,475 | 275 | 275 | 270 |
| Accounts payable and accrued liabilities | 27,593 | 24,718 | 25,195 | 26,281 | 21,358 |
| Accrued Expenses | 959 | 4,563 | 218 | 218 | 218 |
| Other current liabilities | 5,107 | 9,798 | 9,626 | N/A | N/A |
| TOTAL | $51,335 | $54,637 | $47,444 | $41,364 | $32,132 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,691 | 11,737 | 12,937 | 12,937 | 13,212 |
| Deferred Revenues | 13,135 | 14,083 | 12,130 | 13,496 | 9,750 |
| Other Non-Current Liabilities | 7,745 | 9,275 | 7,815 | 8,224 | 6,640 |
| TOTAL | $23,016 | $26,726 | $28,125 | $28,932 | $27,991 |
| Total Liabilities | $74,351 | $81,363 | $75,569 | $70,296 | $60,123 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,312 | 30,330 | 30,256 | 31,118 | 31,808 |
| Common Shares | 357 | 357 | 357 | 356 | 356 |
| Retained earnings | 109,783 | 111,250 | 160,370 | 170,261 | 174,187 |
| Other shareholders' equity | -2,013 | -4,828 | -3,682 | -9,443 | -5,119 |
| TOTAL | $245,740 | $243,743 | $293,541 | $306,961 | $314,893 |
| Total Liabilities And Equity | $320,091 | $325,106 | $369,110 | $377,257 | $375,016 |